ROS1 and neoplasm: While application of precision medicine with therapeutics targeting RTKs yields dramatic responses in LUADs bearing oncogenic EGFR, ALK and ROS1 [1–4, 6–8], chronic control or cures have not yet been realized due to the inevitability of acquired resistance leading to tumor relapse.